Skip to main content

Table 3 Changes in the components of EQ-5D from baseline to day 14 and day 90*

From: Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke

Items

From baseline to Day 14

 

From baseline to Day 90

GDLM group

(N = 1615)

Placebo group

(N = 1604)

Mean difference

(95% CI)

P

value

GDLM group

(N = 1615)

Placebo group

(N = 1604)

Mean difference

(95% CI)

P

value

Mobility

-0.52

(-0.54–0.49)

-0.38

(-0.40–0.35)

-0.14

(-0.17–0.10)

 < 0.0001

-0.78

(-0.80–0.75)

-0.63

(-0.66–0.61)

-0.14

(-0.18–0.11)

 < 0.0001

Usual activities

-0.46

(-0.49–0.44)

-0.36

(-0.38–0.33)

-0.11

(-0.14–0.07)

 < 0.0001

-0.71

(-0.73–0.68)

-0.58

(-0.61–0.56)

-0.12

(-0.16–0.09)

 < 0.0001

Self-care

-0.46

(-0.49–0.44)

-0.36

(-0.38–0.33)

-0.11

(-0.14–0.07)

 < 0.0001

-0.71

(-0.73–0.68)

-0.58

(-0.61–0.56)

-0.12

(-0.16–0.09)

 < 0.0001

Pain/discomfort

-0.41

(-0.43–0.39)

-0.32

(-0.34–0.30)

-0.09

(-0.12–0.06)

 < 0.0001

-0.53

(-0.54–0.51)

-0.44

(-0.46–0.42)

-0.09

(-0.11–0.06)

 < 0.0001

Anxiety/depression

-0.43

(-0.45–0.41)

-0.34

(-0.37–0.32)

-0.08

(-0.12–0.05)

 < 0.0001

-0.55

(-0.57–0.53)

-0.46

(-0.48–0.44)

-0.10

(-0.12–0.07)

 < 0.0001

  1. Abbreviations: CI confidence interval, GDLM Ginkgo diterpene lactone meglumine, MoCA Montreal Cognitive Assessment
  2. The model was adjusted for the corresponding baseline MoCA component and clinical sites